Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

8.880 -0.340 (-3.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 599,369
Open 9.230
Bid (Size) 8.860 (1)
Ask (Size) 9.450 (1)
Prev. Close 9.220
Today's Range 8.700 - 9.430
52wk Range 8.700 - 29.30
Shares Outstanding 91,300,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Small-Cap Stock on Our Watchlist and 2 to Avoid
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
-34.2%
-34.2%
1 Month
-17.2%
-17.2%
3 Month
-34.8%
-34.8%
6 Month
-67.6%
-67.6%
1 Year
-58.6%
-58.6%

More News

Read More
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings?
Via StockStory
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Via Benzinga
Analyst Expectations For Myriad Genetics's Future
Via Benzinga
Expert Outlook: Myriad Genetics Through The Eyes Of 8 Analysts
Via Benzinga
Why Are Myriad Genetics (MYGN) Shares Soaring Today
Via StockStory
This HubSpot Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
Via Benzinga
Why Myriad Genetics (MYGN) Shares Are Plunging Today
Via StockStory
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Via StockStory
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings
Via StockStory
Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops
Via StockStory
Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Announces Senior Leadership Transition
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio
From Myriad Genetics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 24, 2025
Via Benzinga
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Via StockStory
Myriad Genetics Included in Forbes America’s Best Employers 2025 List
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Reasons to Sell MYGN and 1 Stock to Buy Instead
Via StockStory
Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test
From Myriad Genetics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Myriad Genetics, Inc. - Common Stock publicly traded?
Yes, Myriad Genetics, Inc. - Common Stock is publicly traded.
What exchange does Myriad Genetics, Inc. - Common Stock trade on?
Myriad Genetics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Myriad Genetics, Inc. - Common Stock?
The ticker symbol for Myriad Genetics, Inc. - Common Stock is MYGN on the Nasdaq Stock Market
What is the current price of Myriad Genetics, Inc. - Common Stock?
The current price of Myriad Genetics, Inc. - Common Stock is 8.880
When was Myriad Genetics, Inc. - Common Stock last traded?
The last trade of Myriad Genetics, Inc. - Common Stock was at 03/28/25 04:00 PM ET
What is the market capitalization of Myriad Genetics, Inc. - Common Stock?
The market capitalization of Myriad Genetics, Inc. - Common Stock is 810.74M
How many shares of Myriad Genetics, Inc. - Common Stock are outstanding?
Myriad Genetics, Inc. - Common Stock has 811M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.